CoLucid gets $25M

CompanyAmount/RoundLead InvestorsDescription

CoLucid CoLucid Pharmaceuticals
Care Capital

The financing will be used to develop COL-144, a migraine compound, and to advance preclinical pipeline candidates that target neurological and psychiatric disorders.

Immune Design
Alta Partners, The Column Group and Versant Ventures

The vaccine company is developing therapies targeting dendritic cells, which control the human immune response system. And its researchers plan to develop new vaccines as well as enhance existing therapies.

Limerick BioPharma
South San Francisco
Arch Venture Partners, Sevin Rosen Funds and Altitude Funds

Limerick BioPharma will advance its work on the bioavailability of drugs.

CoLucid gets $25M

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.